Arietis Pharma

Executive Summary

Arietis Pharma is a private, early-stage biotechnology company founded in 2018 and based in Cambridge, MA. The company is developing first-in-class small molecule antibiotics that target drug-resistant Gram-positive infections by activating the bacterial ClpP protease, leading to bacterial self-digestion. This novel mechanism of action holds promise for addressing the growing threat of antimicrobial resistance. Arietis remains in a preclinical stage, with no disclosed funding rounds or valuation, and limited public information on its lead candidate or pipeline progress. The company's ability to advance its technology into clinical development and secure financing will be critical to its near-term trajectory.

Upcoming Catalysts (preview)

• Q4 2026Announcement of Series A financing or grant funding40% success
• H1 2027IND filing for lead antibiotic candidate30% success
• Q3 2026Publication or presentation of preclinical proof-of-concept data60% success